JP2011530309A - 多価ワクチン - Google Patents
多価ワクチン Download PDFInfo
- Publication number
- JP2011530309A JP2011530309A JP2011523001A JP2011523001A JP2011530309A JP 2011530309 A JP2011530309 A JP 2011530309A JP 2011523001 A JP2011523001 A JP 2011523001A JP 2011523001 A JP2011523001 A JP 2011523001A JP 2011530309 A JP2011530309 A JP 2011530309A
- Authority
- JP
- Japan
- Prior art keywords
- mosaic
- coverage
- gag
- sequences
- nef
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940031348 multivalent vaccine Drugs 0.000 title description 13
- 238000000034 method Methods 0.000 claims abstract description 39
- 239000000203 mixture Substances 0.000 claims abstract description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 71
- 102000004169 proteins and genes Human genes 0.000 claims description 66
- 239000013598 vector Substances 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 230000028993 immune response Effects 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 230000006698 induction Effects 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 abstract description 104
- 108091007433 antigens Proteins 0.000 abstract description 55
- 102000036639 antigens Human genes 0.000 abstract description 55
- 239000000427 antigen Substances 0.000 abstract description 54
- 230000002163 immunogen Effects 0.000 abstract description 18
- 238000004422 calculation algorithm Methods 0.000 abstract description 12
- 230000002068 genetic effect Effects 0.000 abstract description 10
- 229940033330 HIV vaccine Drugs 0.000 abstract description 5
- 238000002255 vaccination Methods 0.000 abstract description 5
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 62
- 108700004026 gag Genes Proteins 0.000 description 50
- 108700004028 nef Genes Proteins 0.000 description 50
- 238000005457 optimization Methods 0.000 description 38
- 230000004044 response Effects 0.000 description 37
- 238000012360 testing method Methods 0.000 description 31
- 230000006978 adaptation Effects 0.000 description 30
- 210000001744 T-lymphocyte Anatomy 0.000 description 29
- 238000013461 design Methods 0.000 description 28
- 241000700605 Viruses Species 0.000 description 27
- 229940125575 vaccine candidate Drugs 0.000 description 26
- 150000001413 amino acids Chemical class 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 23
- 108091035707 Consensus sequence Proteins 0.000 description 19
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 19
- 238000003491 array Methods 0.000 description 19
- 230000001154 acute effect Effects 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 14
- 241000725303 Human immunodeficiency virus Species 0.000 description 13
- 230000008901 benefit Effects 0.000 description 13
- 208000030507 AIDS Diseases 0.000 description 10
- 241000282560 Macaca mulatta Species 0.000 description 10
- 238000005215 recombination Methods 0.000 description 10
- 230000006798 recombination Effects 0.000 description 10
- 241001430294 unidentified retrovirus Species 0.000 description 10
- 230000005867 T cell response Effects 0.000 description 9
- 230000009260 cross reactivity Effects 0.000 description 9
- 230000003053 immunization Effects 0.000 description 9
- 238000002649 immunization Methods 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 238000009826 distribution Methods 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229940031418 trivalent vaccine Drugs 0.000 description 7
- 241000282693 Cercopithecidae Species 0.000 description 6
- 230000003044 adaptive effect Effects 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 238000002864 sequence alignment Methods 0.000 description 6
- 108010041986 DNA Vaccines Proteins 0.000 description 5
- 229940021995 DNA vaccine Drugs 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 244000309464 bull Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 229940031346 monovalent vaccine Drugs 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 101710091045 Envelope protein Proteins 0.000 description 3
- 108700010908 HIV-1 proteins Proteins 0.000 description 3
- 229940033332 HIV-1 vaccine Drugs 0.000 description 3
- 102100034349 Integrase Human genes 0.000 description 3
- 101710188315 Protein X Proteins 0.000 description 3
- 206010046865 Vaccinia virus infection Diseases 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 229940030156 cell vaccine Drugs 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000000153 supplemental effect Effects 0.000 description 3
- 208000007089 vaccinia Diseases 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 102100034353 Integrase Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000710961 Semliki Forest virus Species 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- 206010058874 Viraemia Diseases 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 108010078428 env Gene Products Proteins 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000007498 myristoylation Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000001814 protein method Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 101150078635 18 gene Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 241001289753 Graphium sarpedon Species 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 101710192141 Protein Nef Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 244000156473 Vallaris heynei Species 0.000 description 1
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 description 1
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- LUTSRLYCMSCGCS-BWOMAWGNSA-N [(3s,8r,9s,10r,13s)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,16-decahydrocyclopenta[a]phenanthren-3-yl] acetate Chemical compound C([C@@H]12)C[C@]3(C)C(=O)CC=C3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 LUTSRLYCMSCGCS-BWOMAWGNSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 238000002986 genetic algorithm method Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229940035036 multi-peptide vaccine Drugs 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000005924 vaccine-induced immune response Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/192,015 US7951377B2 (en) | 2005-08-23 | 2008-08-14 | Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens |
| US12/192,015 | 2008-08-14 | ||
| PCT/US2009/004664 WO2010019262A2 (en) | 2008-08-14 | 2009-08-14 | Polyvalent vaccine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014120307A Division JP2014207910A (ja) | 2008-08-14 | 2014-06-11 | 多価ワクチン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011530309A true JP2011530309A (ja) | 2011-12-22 |
| JP2011530309A5 JP2011530309A5 (enExample) | 2012-10-04 |
Family
ID=41669535
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011523001A Pending JP2011530309A (ja) | 2008-08-14 | 2009-08-14 | 多価ワクチン |
| JP2014120307A Pending JP2014207910A (ja) | 2008-08-14 | 2014-06-11 | 多価ワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014120307A Pending JP2014207910A (ja) | 2008-08-14 | 2014-06-11 | 多価ワクチン |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US7951377B2 (enExample) |
| EP (2) | EP2318430A4 (enExample) |
| JP (2) | JP2011530309A (enExample) |
| CN (1) | CN102177175A (enExample) |
| AU (1) | AU2009282442B2 (enExample) |
| BR (1) | BRPI0917205A2 (enExample) |
| CA (1) | CA2733898C (enExample) |
| IL (1) | IL211184B (enExample) |
| WO (1) | WO2010019262A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016533181A (ja) * | 2013-10-16 | 2016-10-27 | ニユー・イングランド・バイオレイブス・インコーポレイテツド | 強化された特性を有する逆転写酵素 |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8119140B2 (en) | 2005-08-23 | 2012-02-21 | Los Alamos Security, LLC | Immunogenic compositions comprising human immunodeficiency virus (HIV) mosaic Nef proteins |
| US7951377B2 (en) | 2005-08-23 | 2011-05-31 | Los Alamos National Security, Llc | Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens |
| PL2358757T3 (pl) | 2008-11-18 | 2019-02-28 | Beth Israel Deaconess Medical Center | Szczepionki antywirusowe o ulepszonej immunogenności komórkowej |
| US10040826B2 (en) | 2011-07-05 | 2018-08-07 | Duke University | Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens |
| EP2763699A4 (en) | 2011-10-03 | 2015-05-20 | Univ Duke | VACCINE |
| AU2013358951C1 (en) | 2012-12-13 | 2019-06-27 | Baylor Research Institute | Triheptanoin for the treatment of glucose transporter 1 deficiency |
| ES2957209T3 (es) * | 2013-09-30 | 2024-01-15 | Triad Nat Security Llc | Polipéptidos inmunogénicos mosaicos del VIH de región conservada |
| US10149902B2 (en) | 2014-03-19 | 2018-12-11 | Duke University | Swarm immunization with envelopes from CH505 |
| AU2015236147A1 (en) * | 2014-03-25 | 2016-10-13 | Duke University | Mosaic HIV-1 sequences and uses thereof |
| CA2944068A1 (en) | 2014-03-31 | 2015-10-08 | Duke University | Compositions comprising ch848 envelopes and uses thereof |
| CA2962938A1 (en) | 2014-09-28 | 2016-03-31 | Duke University | Compositions comprising ch505 envelopes, and trimers |
| EP3423472A4 (en) | 2016-03-01 | 2019-12-25 | Duke University | COMPOSITIONS WITH HIV COVERS FOR INDUCING CH235 CELL LINE ANTIBODIES |
| CA3016352A1 (en) | 2016-03-03 | 2017-09-08 | Duke University | Compositions and methods for inducing hiv-1 antibodies |
| US11318197B2 (en) | 2016-03-03 | 2022-05-03 | Duke University | Compositions and methods for inducing HIV-1 antibodies |
| EP3519428A4 (en) | 2016-10-03 | 2020-07-08 | Duke University | METHODS OF IDENTIFYING IMMUNOGENS BY TARGETING IMPROBABLE MUTATIONS |
| EP3526236B1 (en) * | 2016-10-17 | 2025-12-10 | Beth Israel Deaconess Medical Center, Inc. | Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same |
| WO2018218225A1 (en) | 2017-05-25 | 2018-11-29 | Duke University | Compositions comprising modified hiv envelopes |
| US12138304B2 (en) | 2018-10-01 | 2024-11-12 | Duke University | HIV-1 envelope stabilizing mutations |
| AU2020315598B2 (en) | 2019-07-16 | 2024-12-12 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
| WO2021081437A2 (en) | 2019-10-23 | 2021-04-29 | Duke University | Compositions comprising v2 opt hiv envelopes |
| CA3202466A1 (en) | 2021-01-14 | 2022-07-21 | Jiani LI | Hiv vaccines and methods of using |
| CA3206343A1 (en) | 2021-01-28 | 2022-08-04 | Rory HENDERSON | Compositions comprising hiv envelopes to induce hiv-1 antibodies |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005028625A2 (en) * | 2003-09-17 | 2005-03-31 | Duke University | Consensus/ancestral immunogens |
| US20050137387A1 (en) * | 2000-02-18 | 2005-06-23 | University Of Washington Office Of Technology Licensing | Ancestral and COT viral sequences, proteins and immunogenic compositions |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6139843A (en) | 1991-04-02 | 2000-10-31 | Albert Einstein College Of Medicine Of Yeshiva University | Peptide compositions for the treatment of HIV |
| US6541011B2 (en) | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
| US6503753B1 (en) | 1998-02-13 | 2003-01-07 | Adan Rios | Method for the development of an HIV vaccine |
| US20030180314A1 (en) | 1998-07-10 | 2003-09-25 | Degroot Anne | Immunogenic, cross-clade, HIV peptides |
| US7935805B1 (en) * | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| US6710173B1 (en) * | 1999-06-25 | 2004-03-23 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
| US20040115621A1 (en) | 2000-02-18 | 2004-06-17 | Allen Rodrigo | Ancestral viruses and vaccines |
| US6733993B2 (en) | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
| CA2466050A1 (en) | 2001-11-07 | 2003-05-15 | Duke University | Polyvalent immunogen |
| US7195768B2 (en) | 2001-11-07 | 2007-03-27 | Duke University | Polyvalent immunogen |
| WO2005012502A2 (en) * | 2003-03-28 | 2005-02-10 | Idm Pharma, Inc. | Methods of identifying optimal variants of peptide epitopes |
| US7425611B2 (en) | 2003-03-28 | 2008-09-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Immunogenic HIV-1 multi-clade, multivalent constructs and methods of their use |
| CN1913919B (zh) | 2003-09-15 | 2011-10-19 | 美国政府健康及人类服务部 | 基于hiv多进化枝的env的hiv疫苗 |
| WO2005035555A1 (en) * | 2003-10-10 | 2005-04-21 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv/siv env chimeras that promote trimerization and maintain targets of neutralizing antibodies |
| US7951377B2 (en) | 2005-08-23 | 2011-05-31 | Los Alamos National Security, Llc | Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens |
| US8119140B2 (en) | 2005-08-23 | 2012-02-21 | Los Alamos Security, LLC | Immunogenic compositions comprising human immunodeficiency virus (HIV) mosaic Nef proteins |
| CA2626257A1 (en) | 2005-10-17 | 2007-04-26 | Novartis Ag | Multiclade hiv vaccines |
| WO2012047267A2 (en) | 2010-09-28 | 2012-04-12 | Duke University | Polyvalent immunogen |
-
2008
- 2008-08-14 US US12/192,015 patent/US7951377B2/en not_active Expired - Fee Related
-
2009
- 2009-08-14 US US12/737,761 patent/US9044445B2/en not_active Expired - Fee Related
- 2009-08-14 EP EP09806982A patent/EP2318430A4/en not_active Withdrawn
- 2009-08-14 CN CN2009801404211A patent/CN102177175A/zh active Pending
- 2009-08-14 BR BRPI0917205A patent/BRPI0917205A2/pt not_active IP Right Cessation
- 2009-08-14 WO PCT/US2009/004664 patent/WO2010019262A2/en not_active Ceased
- 2009-08-14 CA CA2733898A patent/CA2733898C/en not_active Expired - Fee Related
- 2009-08-14 EP EP16184203.4A patent/EP3178842B1/en not_active Not-in-force
- 2009-08-14 AU AU2009282442A patent/AU2009282442B2/en not_active Ceased
- 2009-08-14 JP JP2011523001A patent/JP2011530309A/ja active Pending
-
2011
- 2011-02-10 IL IL211184A patent/IL211184B/en active IP Right Grant
- 2011-04-26 US US13/094,734 patent/US9011873B2/en not_active Expired - Fee Related
-
2014
- 2014-06-11 JP JP2014120307A patent/JP2014207910A/ja active Pending
-
2015
- 2015-04-17 US US14/689,995 patent/US9821053B2/en not_active Expired - Fee Related
- 2015-05-29 US US14/726,373 patent/US9844590B2/en not_active Expired - Fee Related
-
2017
- 2017-12-15 US US15/843,233 patent/US20180185471A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050137387A1 (en) * | 2000-02-18 | 2005-06-23 | University Of Washington Office Of Technology Licensing | Ancestral and COT viral sequences, proteins and immunogenic compositions |
| WO2005028625A2 (en) * | 2003-09-17 | 2005-03-31 | Duke University | Consensus/ancestral immunogens |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016533181A (ja) * | 2013-10-16 | 2016-10-27 | ニユー・イングランド・バイオレイブス・インコーポレイテツド | 強化された特性を有する逆転写酵素 |
Also Published As
| Publication number | Publication date |
|---|---|
| US9844590B2 (en) | 2017-12-19 |
| US20180185471A1 (en) | 2018-07-05 |
| US9821053B2 (en) | 2017-11-21 |
| AU2009282442A1 (en) | 2010-02-18 |
| WO2010019262A3 (en) | 2010-05-27 |
| BRPI0917205A2 (pt) | 2015-11-10 |
| EP3178842A1 (en) | 2017-06-14 |
| EP2318430A4 (en) | 2012-08-29 |
| WO2010019262A2 (en) | 2010-02-18 |
| US9044445B2 (en) | 2015-06-02 |
| JP2014207910A (ja) | 2014-11-06 |
| US20150265700A1 (en) | 2015-09-24 |
| CA2733898C (en) | 2017-06-20 |
| IL211184B (en) | 2019-02-28 |
| US20160067329A1 (en) | 2016-03-10 |
| CA2733898A1 (en) | 2010-02-18 |
| US20110301328A1 (en) | 2011-12-08 |
| IL211184A0 (en) | 2011-04-28 |
| US9011873B2 (en) | 2015-04-21 |
| US20120121631A1 (en) | 2012-05-17 |
| US7951377B2 (en) | 2011-05-31 |
| AU2009282442B2 (en) | 2015-06-04 |
| CN102177175A (zh) | 2011-09-07 |
| EP2318430A2 (en) | 2011-05-11 |
| US20090198042A1 (en) | 2009-08-06 |
| EP3178842B1 (en) | 2020-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9044445B2 (en) | Mosaic clade M human immunodeficiency virus type 1 (HIV-1) gag immunogens | |
| US9492532B2 (en) | Nucleic acids encoding mosaic HIV-1 gag proteins | |
| O’Connell et al. | Human immunodeficiency virus vaccine trials | |
| AU2004279362B2 (en) | HIV vaccines based on ENV of multiple clades of HIV | |
| Bojak et al. | The past, present and future of HIV-vaccine development: a critical view | |
| EP1667523B1 (en) | Dna vaccine compositions and methods of use | |
| US20170107260A1 (en) | Mosaic hiv-1 sequences and uses thereof | |
| AU2015221518A1 (en) | Polyvalent Vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120814 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120814 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140131 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140430 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140509 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140602 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140609 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140611 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140611 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20141224 |